Array Amgen and BioPharma Partner in Type 2 Diabetes Array BioPharma Inc click here . and Amgen Inc. today announced that they entered into an contract granting Amgen exclusive worldwide rights to Array’s small-molecule glucokinase activator program, including ARRY-403, becoming tested in a Phase 1 scientific trial in patients with Type 2 diabetes. Beneath the terms of the agreement, Array will receive an upfront payment of $60 million and additional contingent payments for several clinical and industrial milestones. Array is responsible for completing the Phase 1 trial for ARRY-403. Amgen is in charge of future clinical advancement and commercialization for ARRY-403 and any resulting back-up compounds, with Array having a choice to co-promote in the United States.

The Hill: ‘Minnesota Gov. Tim Pawlenty is joining a lawsuit challenging the constitutionality of the new health rules over the recommendation of the state’s best law enforcement recognized. Pawlenty is usually a potential 2012 GOP presidential applicant and the lawsuit is among the most highly-visible ways that Republicans want to dismantle the measure. The governor asked Lawyer General Lori Swanson last month to examine the legality of the expenses, and she ultimately discovered that the lawsuit is ‘not warranted” .